Phio Pharmaceuticals appoints David H. Deming to Board of Directors, effective Feb 19, 2025

Phio Pharmaceuticals Corp.

Board expanded to six members; five of six are independent directors.
Deming will serve on the Nominating Committee immediately.
Over 30 years in investment banking; 27 years at JP Morgan leading Health Group in M&A.
Appointment effective February 19, 2025; term until 2025 annual meeting.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

David H. Deming

Director

PHIO · Phio Pharmaceuticals Corp.

Effective: 2025-02-19
Filed: February 20, 2025, 6:59 PM ET

Effective as of February 19, 2025, the Board of Directors (the “Board”) of Phio Pharmaceuticals Corp. (the “Company”) increased the size of the Board to six members and appointed Mr. David H. Deming to serve on the Board until the 2025 annual meeting of stockholders.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

David H. Deming was appointed as Director at Phio Pharmaceuticals Corp..

Action: appointed
Role: Director

Exact text from the filing

Effective as of February 19, 2025, the Board of Directors (the “Board”) of Phio Pharmaceuticals Corp. (the “Company”) increased the size of the Board to six members and appointed Mr. David H. Deming to serve on the Board until the 2025 annual meeting of stockholders.

View on SEC.gov

Phio Pharmaceuticals Corp. filing history →

Source: SEC EDGAR

accession 0001683168-25-001137

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.